Biosante Pharmaceuticals Aktie
WKN DE: A1W15D / ISIN: US00182C1036
|
02.01.2025 13:08:15
|
ANI Pharma Launches FDA-Approved Prucalopride Tablets With 180-Day CGT Exclusivity
(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) announced Thursday the launch of Prucalopride Tablets, which is the generic version of the reference listed drug (RLD) Motegrity.
The launch follows the final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA)
The FDA has granted Prucalopride Tablets a Competitive Generic Therapy (CGT) designation, with 180-day exclusivity. U.S. annual sales for Prucalopride Tablets total approximately $168.0 million, based on October 2024 moving annual total (MAT) IQVIA data.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Biosante Pharmaceuticals Incmehr Nachrichten
|
07.08.25 |
Ausblick: Biosante Pharmaceuticals veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) | |
|
08.05.25 |
Ausblick: Biosante Pharmaceuticals zieht Bilanz zum abgelaufenen Quartal (finanzen.net) |
Analysen zu Biosante Pharmaceuticals Incmehr Analysen
Aktien in diesem Artikel
| Biosante Pharmaceuticals Inc | 77,50 | -7,74% |
|